4-Methoxybenzyl 2-hydroxyacetate | 102991-08-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Methoxybenzyl 2-hydroxyacetate
• 英文别名: 4-Methoxybenzyl glycolate；(4-methoxyphenyl)methyl 2-hydroxyacetate
• CAS: 102991-08-2
• 化学式: C₁₀H₁₂O₄
• 分子量: 196.203
• InChiKey: NBBDCFZVMVAUSI-UHFFFAOYSA-N

物化性质

• 沸点：
  318.0±22.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-Methoxybenzyl 2-hydroxyacetate 在 sodium hydride 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 mineral oil 为溶剂， 反应 62.25h， 生成 4-methoxybenzyl 2-((6-amino-5-(((4-((1r,4r)-4-(2-methoxy-2-oxoethyl)cyclohexyl)phenyl)amino)methyl)pyrimidin-4-yl)oxy)acetate
  参考文献：
  名称：

  Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor

  摘要：

  DGAT-1 is an enzyme that catalyzes the final step in triglyceride synthesis. mRNA knockout experiments in rodent models suggest that inhibitors of this enzyme could be of value in the treatment of obesity and type II diabetes. The carboxylic acid-based DGAT-1 inhibitor 1 was advanced to clinical trials for the treatment of type 2 diabetes, despite of the low passive permeability of 1. Because of questions relating to the potential attenuation of distribution and efficacy of a poorly permeable agent, efforts were initiated to identify compounds with improved permeability. Replacement of the acid moiety in 1 with an oxadiazole led to the discovery of 52, which possesses substantially improved passive permeability. The resulting pharmacodynamic profile of this neutral DGAT-1 inhibitor was found to be similar to 1 at comparable plasma exposures. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.06.045
• 作为产物：
  描述：

  羟基乙酸 、 4-甲氧基氯苄 在 碳酸氢钠 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 4-Methoxybenzyl 2-hydroxyacetate
  参考文献：
  名称：

  AMIDE DERIVATIVE

  摘要：

  提供一种具有优异降血糖作用的化合物，或其药用盐，以及一种具有优异治疗作用和/或预防作用的药物组合物，对于引起血糖水平增高的糖代谢异常导致的1型糖尿病、2型糖尿病等具有良好疗效。公开了一种由通用式(I)表示的化合物，或其药用盐。

  公开号：

  US20120129832A1

文献信息

• Water-soluble triazole fungicide
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040198790A1

  公开（公告）日：2004-10-07

  A triazole compound of the formula (I) or a pharmacologically salt thereof: 1 wherein X represents a group of formula X—OH which has antifungal activity, L represents an -(adjacently substituted C 6 -C 10 aryl)-CH 2 group and R represents a —P(═O)(OH) 2 group.

  一种三唑类化合物，其化学式为（I），或其药理学盐：1其中X代表具有抗真菌活性的化合物X—OH，L代表-(相邻取代的C6-C10芳基)-CH2基团，R代表—P(═O)(OH)2基团。
• Amide derivative
  申请人：Yamanoi Shigeo

  公开号：US08557802B2

  公开（公告）日：2013-10-15

  Provided are a compound having an excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.

  提供一种具有优异降血糖作用的化合物或其药学上可接受的盐，并且提供一种具有优异治疗和/或预防1型糖尿病、2型糖尿病等因异常糖代谢导致血糖升高的药物组合物。公开了一种由通式（I）表示的化合物或其药学上可接受的盐。
• WATER-SOLUBLE TRIAZOLE FUNGICIDE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1362856B1

  公开（公告）日：2008-09-10
• Synthesis, cleavage, and antifungal activity of a number of novel, water-soluble ester prodrugs of antifungal triazole CS-758
  作者：Yoshiko Kagoshima、Makoto Mori、Eiko Suzuki、Takahiro Shibayama、Tamako Iida、Yasuki Kamai、Toshiyuki Konosu

  DOI：10.1016/j.bmcl.2009.04.135

  日期：2009.7

  In this study, the synthesis and evaluation of a number of esters of CS-758 as injectable prodrugs are described. Phosphoryl ester 1a was soluble in water (> 30 mg/mL) and was converted to CS-758 in human liver microsome. It was also converted to CS- 758 in rats after iv administration, wherein the bioavailability of CS- 758 was 53%. Compound 1a ( iv) reduced the viable cell counts in kidneys in a murine systemic Candida albicans infection model, wherein the effect was comparable to or slightly superior to that of CS-58 (po). The prodrug 1a proved to be a promising injectable antifungal agent whose further evaluation is warranted. (C) 2009 Elsevier Ltd. All rights reserved.
• 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2463279B1

  公开（公告）日：2014-02-12